SAB BIO to Participate in Upcoming Investor Conferences
January 31, 2025 07:00 ET
|
SAB Biotherapeutics, Inc.
MIAMI, Jan. 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing...
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
January 28, 2025 07:00 ET
|
SAB Biotherapeutics, Inc.
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy
January 23, 2025 07:00 ET
|
SAB Biotherapeutics, Inc.
SAB to host webinar event to discuss Phase 1 clinical trial topline results
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
November 06, 2024 17:05 ET
|
SAB Biotherapeutics, Inc.
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
October 31, 2024 07:00 ET
|
SAB Biotherapeutics, Inc.
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
September 13, 2024 07:00 ET
|
SAB Biotherapeutics, Inc.
MIAMI, Sept. 13, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human...
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting
September 09, 2024 07:00 ET
|
SAB Biotherapeutics, Inc.
SAB BIO presents clinical trial progress update at EASD conference
SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting
September 04, 2024 07:05 ET
|
SAB Biotherapeutics, Inc.
MIAMI, Sept. 04, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human...
SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates
August 08, 2024 17:51 ET
|
SAB Biotherapeutics, Inc.
FDA provided clearance to SAB’s IND Appointed Lucy To as Chief Financial Officer Announced founding of a new Clinical Advisory Board MIAMI, Aug. 08, 2024 (GLOBE NEWSWIRE) -- SAB BIO...
SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes
August 05, 2024 07:30 ET
|
SAB Biotherapeutics, Inc.
MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing...